Abstract
摘要
相似文献
1
Oral hypoglycaemics.
Aust Fam Physician. 2010 Nov;39(11):812.
2
[Sitagliptin].[西他列汀]
Rev Infirm. 2008 Oct(144):46-8.
3
[DPP-4 inhibitors in clinical use. Therapy without the risk of hypoglycaemia].[临床应用的二肽基肽酶-4抑制剂。无低血糖风险的治疗方法]
Pharm Unserer Zeit. 2010 Mar;39(2):114-8. doi: 10.1002/pauz.201000358.
4
DPP-4 inhibitors and angioedema: a cause for concern?二肽基肽酶-4抑制剂与血管性水肿：值得关注的原因？
Ann Allergy Asthma Immunol. 2011 May;106(5):436-8. doi: 10.1016/j.anai.2011.02.012. Epub 2011 Mar 22.
5
Q: Do incretin drugs for type 2 diabetes increase the risk of acute pancreatitis?问：用于2型糖尿病的肠促胰岛素药物会增加急性胰腺炎的风险吗？
Cleve Clin J Med. 2010 Aug;77(8):503-5. doi: 10.3949/ccjm.77a.09167.
6
Alogliptin, a potent and selective dipeptidyl peptidase-IV inhibitor for the treatment of type 2 diabetes.阿格列汀，一种用于治疗2型糖尿病的强效选择性二肽基肽酶-IV抑制剂。
Curr Opin Investig Drugs. 2008 Apr;9(4):402-13.
7
The development of angioedema in a patient with type 2 diabetes due to a novel dipeptidyl peptidase-IV inhibitor, anagliptin.一名2型糖尿病患者因新型二肽基肽酶-4抑制剂阿格列汀发生血管性水肿。
Int J Cardiol. 2013 Oct 3;168(3):e106. doi: 10.1016/j.ijcard.2013.07.257. Epub 2013 Aug 2.
8
[Oral Linagliptin (Trajenta)].口服利格列汀（欧唐静）
J Pharm Belg. 2013 Mar(1):41-3.
9
Dipeptidyl peptidase-4 inhibitors and cardiovascular outcomes: decongesting the matter.二肽基肽酶-4抑制剂与心血管结局：理清相关问题
Eur Heart J. 2015 Jun 21;36(24):1497-8.
10
Alogliptin (nesina) for type 2 diabetes.
Med Lett Drugs Ther. 2013 May 27;55(1417):41-3.
Zotero 插件